Clinical study on of combination therapy with a DPP-4 inhibitor and a mitiglinide/voglibose fixed-dose combination (the combination) on glycemic/metabolic responses after meals in patients with type 2 diabetic mellitus (T2DM)
Not Applicable
- Conditions
- T2DM
- Registration Number
- JPRN-UMIN000012294
- Lead Sponsor
- Yuri Ono Clinic, Diabetes, Internal Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 12
Inclusion Criteria
Not provided
Exclusion Criteria
1)Patients to whom [Contraindications] in labeling for the combination apply 2)Any others who the principal investigator deems unsuitable as subjects, in consideration of any [Special caution needed] in labeling for the combination
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy endpoints are the actual measured value of glycemic/metabolic parameters over 120 minutes after each meal, the changes from baseline and the AUC over 120 minutes after each meal of breakfast, lunch and dinner in each treatment period.
- Secondary Outcome Measures
Name Time Method